https://www.pharmaradar360.com/article/ad6504852721b264PharmaRadar360en2026-04-13T05:00:00.000ZRoche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosishttps://www.pharmaradar360.com/article/02af197f88ab392bPharmaRadar360en2026-04-13T03:00:00.000Z[IBENTO][IBENTO]The report for the PMDA-ATC Pharmacovigilance Seminar 2026 has been posted.https://www.pharmaradar360.com/article/1f15d45363267479PharmaRadar360en2026-04-13T03:00:00.000Z[SONOTA]Recent Publications by PMDA Staff updatedhttps://www.pharmaradar360.com/article/14b95a4514bb1516PharmaRadar360en2026-04-13T03:00:00.000Z[KOKUSAI]The report for the APEC CoE workshop: PMDA-ATC Pharacovigilance Seminar 2026 has been posted.https://www.pharmaradar360.com/article/4d6870b38d5595e3PharmaRadar360en2026-04-13T03:00:00.000Z[KOKUSAI]PMDA-ATC E-Learning Course contents have been released for FY2026https://www.pharmaradar360.com/article/82c82f3e675d6931PharmaRadar360en2026-04-13T00:00:00.000ZSysmex to Serve as Special Sponsor of Kobe Marathon 2026 – Supporting the Event Toward a Healthy, Prosperous Society and Vibrant Local Communities –https://www.pharmaradar360.com/article/203a3efa16b1304cPharmaRadar360en2026-04-13T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/5df511eb97b201f2PharmaRadar360en2026-04-13T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/2c80a3ff78b576d8PharmaRadar360en2026-04-13T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/439b95cd7a2c5901PharmaRadar360en2026-04-13T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/68c96c3452096872PharmaRadar360en2026-04-13T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/bf2ae43ac3a8225fPharmaRadar360en2026-04-13T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/7e58ed1119f2b704PharmaRadar360en2026-04-13T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/0ce94e38bf999702PharmaRadar360en2026-04-13T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/e85ab22e547244adPharmaRadar360en2026-04-13T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/e418c83ae7f230f9PharmaRadar360en2026-04-13T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/c7f20c9aa9485624PharmaRadar360en2026-04-13T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/47c4b09686b67145PharmaRadar360en2026-04-13T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/1ce2024dfd0d2bd1PharmaRadar360en2026-04-13T00:00:00.000Z6203https://www.pharmaradar360.com/article/12cff47269c5dc28PharmaRadar360en2026-04-13T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/8d8c391caf92f7f3PharmaRadar360en2026-04-12T14:10:11.000ZGSK plans five Phase 3 studies for gynecological cancer ADC from Hansohhttps://www.pharmaradar360.com/article/d10b0fa4924d152fPharmaRadar360en2026-04-12T12:00:00.000ZGSK presents positive data for B7-H4-targeted ADC in gynaecological cancershttps://www.pharmaradar360.com/article/6539ba502e680f06PharmaRadar360en2026-04-12T11:15:00.000ZAbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026https://www.pharmaradar360.com/article/2a5ffed9f4929861PharmaRadar360en2026-04-11T10:00:58.000ZMore pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more